WO2011139595A4 - Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain - Google Patents
Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain Download PDFInfo
- Publication number
- WO2011139595A4 WO2011139595A4 PCT/US2011/033545 US2011033545W WO2011139595A4 WO 2011139595 A4 WO2011139595 A4 WO 2011139595A4 US 2011033545 W US2011033545 W US 2011033545W WO 2011139595 A4 WO2011139595 A4 WO 2011139595A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymeric substrate
- therapeutic agent
- poly
- peo
- hydrocortisone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3401—Puncturing needles for the peridural or subarachnoid space or the plexus, e.g. for anaesthesia
Abstract
The invention describes a device for administering a therapeutic agent to a subject at a sustained rate over a period of time, the device being shaped, sized and adapted for administering the therapeutic agent into the region of the spinal column of the subject, the device comprising: an elongated first polymeric substrate having a proximal end, a distal end and diameter or width of about 1 mm to about 10 mm and a length of about 4 cm to about 35 cm; optionally, an elongated second polymeric substrate positioned within the first polymeric substrate; and at least one therapeutic agent, loaded into or onto the first polymeric substrate or second polymeric substrate or both, wherein the therapeutic agent is available for diffusion into the region of the spinal column of the subject.
Claims
1. A device for administering a therapeutic agent to a subject at a sustained rate over a period of time, the device being shaped, sized and adapted for administering the therapeutic agent into the region of the spinal column of the subject, the device comprising:
an elongated first polymeric substrate having a proximal end, a distal end and diameter or width of about 1 mm to about 10 mm and a length of about 4 cm to about 35 cm;
optionally, an elongated second polymeric substrate positioned within the first polymeric substrate; and
at least one therapeutic agent, loaded into or onto the first polymeric substrate or second polymeric substrate or both, wherein the therapeutic agent is available for diffusion into the region of the spinal column of the subject.
2. The device of claim 1 , wherein the first polymeric substrate is in the form of a rod, a tube, a ribbon or rectangle.
3. The device of either of claims 1 or 2, wherein the second polymeric substrate is in the form of a rod, a tube, a ribbon, a rectangle or string.
4. The device of any of claims 1 through 3, wherein the polymers of the first and second polymeric substrate are silicone, polyurethane, polyether urethane, polyether urethane urea, polyamide, polyacetal, polyester, poly(ethylene- chlorotrifluoroethylene), poly tetrafluoroethylene (Teflon), styrene butadiene rubber, polyethylene, polypropylene, polyphenylene oxide-polystyrene, poly-a- chloro-p-xylene, polymethylpentene, polysulfone poly(alpha-hydroxy acids), poly(lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PLG), polyethylene glycol (PEG), PEG conjugates of poly(alpha-hydroxy acids), polyorthoesters, polyaspirins, polyphosphazenes, vinylpyrrolidone, polyvinyl alcohol (PVA), PVA-g-PLGA, polyethylene glycol-terephthalate and
polybutylene-terephthalate (PEGT-PBT) copolymer(polyactive), methacrylates, poly(N-isopropylacrylamide), polyethylene oxides (as known as polyoxyethylene or PEO), poly-propylene oxide (also known as polyoxypropylene or PPO), poly(aspartic acid) (PAA), PEO-PPO-PEO (Pluronics®, BASF), PEO-PPO-PAA copolymers, PLGA-PEO-PLGA, or mixtures thereof.
5. The device of any of claims 1 through 3, wherein the at least one of the polymers of the first and second polymeric substrate is a shape memory polymer.
6. The device of claim 5, wherein the shape memory polymer is oligo(e- caprolactone)diol and cry stallis able oligo(p-dioxanone)diol.
7. The device of any of claims 1 through 6, wherein the therapeutic agent is an analgesic.
8. The device of claim 7, wherein the analgesic is morphine naloxone, codeine, oxycodone, hydrocodone, diamorphine, pethidine, tramadol, tapentadol, buprenorphine, bupivacaine, bupivacaine (L-isomer), ropivacaine, mupivacaine, lidocaine, capsaicin, clonidine, or mixtures thereof.
9. The device of any of claims 1 through 6, wherein the therapeutic agent is a muscle relaxant.
10. The device of claim 9, wherein the muscle relaxant is baclofen, baclofen (L-isomer), midazolam, tizanidine or mixtures thereof.
11. The device of any of claims 1 through 6, wherein the therapeutic agent is an anti-inflammatory.
12. The device of claim 11 , wherein the anti-inflammatory is hydrocortisone, Cortisol, hydroxyltriamcinolone, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluocinolone acetonide, fluocinonide, flucortine butylesters, fluocortolone, fluprednidene(fluprednylidene)acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolone, fludrocortisone, diflurosone diacetate, fluocinolone, fluradrenolone acetonide, medrysone, amcinafel, amcinafide, betamethasone and the balance of its esters,
chloroprednisone, chlorprednisone acetate, clocortelone, clescinolone, dichlorisone, diflurprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone
cyclopentylpropionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone, acetaminophen, paracetamol, nabumetone, celecoxib, etodolac, nimesulide, apasone, gold, piroxicam, isoxicam, meloxicam, tenoxicam, sudoxicam, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal, diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, ketorolac, mefenamic, meclofenamic, flufenamic, niflumic, ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, ketorolac, sulfasalazine, indopropfen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic, phenylbutazone, oxyphenbutazone, feprazone, azapropazone, trimethazone or mixtures thereof.
13. The device of any of claims 1 through 12, wherein the therapeutic agent is in or on the first polymeric substrate.
14. The device of any of claims 1 through 12, wherein the therapeutic agent is in or on the second polymeric substrate.
32
15. The device of any of; claims .1 through 12, wherein the device configuration is a tube and the therapeutic agent is contained within a hollow portion of the first polymeric substrate.
33
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32843610P | 2010-04-27 | 2010-04-27 | |
US61/328,436 | 2010-04-27 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011139595A2 WO2011139595A2 (en) | 2011-11-10 |
WO2011139595A3 WO2011139595A3 (en) | 2012-05-31 |
WO2011139595A4 true WO2011139595A4 (en) | 2012-08-16 |
Family
ID=44904311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/033545 WO2011139595A2 (en) | 2010-04-27 | 2011-04-22 | Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011139595A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
CA2890270A1 (en) * | 2012-11-01 | 2014-05-08 | Torrent Pharmaceuticals Ltd | Pharmaceutical composition of tapentadol for parenteral administration |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
ITMI20131453A1 (en) * | 2013-09-05 | 2015-03-06 | Francesco Ugo Prada | ULTRA-COMPATIBLE ARTIFICIAL CRANIOTOMIC OPERCOLO |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
DK3169315T3 (en) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Liquid-filled dosage form to prevent immediate release abuse |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
CN107789628B (en) * | 2016-12-29 | 2021-07-23 | 天津键凯科技有限公司 | Application of conjugate of polyethylene glycol and local anesthetic in non-anesthesia analgesia |
WO2021237321A1 (en) * | 2020-05-29 | 2021-12-02 | Luiz Peracchi Edson | Long-lasting reabsorbable subcutaneous implant with sustained release of pre-concentrated pharmacologically active substance in polymer for the treatment of chronic adrenal insufficiency or hypocortisolism |
JP2023542784A (en) | 2020-07-25 | 2023-10-12 | ファーマフィナ アイラック サティス ヴェエ パザルラマ アノニム シルケティ | Combinations of drugs in parenteral dosage forms for long-term anesthesia |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4917686A (en) | 1985-12-16 | 1990-04-17 | Colorado Biomedical, Inc. | Antimicrobial device and method |
US5245098A (en) | 1992-01-21 | 1993-09-14 | The University Of Akron | Process for preparation of non-conjugated diolefins |
CA2316945A1 (en) | 1998-02-23 | 1999-08-26 | Mnemoscience Gmbh | Shape memory polymers |
JP2004530573A (en) | 2001-01-24 | 2004-10-07 | ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド | Shape of ophthalmic lens using shape memory polymer or shape memory alloy and method of manufacturing ophthalmic product using the shape |
DE10217350C1 (en) | 2002-04-18 | 2003-12-18 | Mnemoscience Gmbh | polyesterurethanes |
US7794476B2 (en) * | 2003-08-08 | 2010-09-14 | Warsaw Orthopedic, Inc. | Implants formed of shape memory polymeric material for spinal fixation |
US7557167B2 (en) | 2006-09-28 | 2009-07-07 | Gore Enterprise Holdings, Inc. | Polyester compositions, methods of manufacturing said compositions, and articles made therefrom |
US20090123508A1 (en) * | 2007-10-04 | 2009-05-14 | Boston Scientific Scimed, Inc. | Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management |
-
2011
- 2011-04-22 WO PCT/US2011/033545 patent/WO2011139595A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2011139595A3 (en) | 2012-05-31 |
WO2011139595A2 (en) | 2011-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011139595A4 (en) | Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain | |
CN109069812B (en) | Microneedles using bioabsorbable metals | |
BR112013009609A2 (en) | silk fibroin microneedles and methods for making them | |
Baek et al. | Drug-coated microneedles for rapid and painless local anesthesia | |
Milewski et al. | Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin | |
Ullah et al. | Porous polymer coatings on metal microneedles for enhanced drug delivery | |
JP2018141023A (en) | Microarray for delivery of therapeutic agent and methods of use | |
US10932709B2 (en) | Sensors for continuous analyte monitoring, and related methods | |
AU2010241740B2 (en) | Devices and methods for treating pain associated with tonsillectomies | |
CN107206221B (en) | Microneedle arrays and methods of use | |
WO2006101459A1 (en) | Microneedles | |
EP3128902B1 (en) | Sensor for continuous analyte monitoring | |
JP2009501066A (en) | Solid microneedle and manufacturing method thereof | |
US10799289B2 (en) | Compositions, systems, kits, and methods for neural ablation | |
CO6341545A2 (en) | METHOD FOR DEVELOPING A MICROPHASE OF SUSTAINED LIBERATION THROUGH A SOLVENT EVAPORATION METHOD | |
MX2011006527A (en) | Dipeptide linked medicinal agents. | |
CN108601932A (en) | Microneedle array and micropin piece | |
US20090035354A1 (en) | Device and Method for Treating the Anal Sphincter | |
JP2009540894A (en) | Flexible device for introducing a medical device into the body | |
WO2020252077A1 (en) | Methods, devices and compositions for local delivery | |
KR20180080476A (en) | The multi-step stuctured microneedle patch and the producing method for the same | |
US10197498B2 (en) | Compositions and methods for measurement of analytes | |
JP2007037885A (en) | Apparatus and method for endermic drug delivery and manufacturing method of needle for endermic drug delivery apparatus | |
JP2009066104A (en) | Microneedle structure and microneedle structure device | |
Zhou et al. | Bridging the gap between invasive and noninvasive medical care: emerging microneedle approaches |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11716795 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct app. not ent. europ. phase |
Ref document number: 11716795 Country of ref document: EP Kind code of ref document: A2 |